1上海中医药大学研究生院201203；2上海健康医学院附属周浦医院内分泌-风湿科201318；3上海中医药大学201203
网络出版日期: 2025-08-16
基金资助
国家自然科学基金（81873636）；上海市重点专科项目（ZK2019C09）；浦东新区卫生健康委员会卫生科研项目（PW2019D-12）；浦东新区周浦医院青年基金项目（ZPXM-2019A-02）
Clinical application progress of cytotoxic T lymphocyte antigen 4-based biological agents
1Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; 2Depertment of Endocrinology & Rheumatology, Shanghai University of Medicine ＆ Health Science Affiliated Zhoupu Hospital, Shanghai 201318, China; 3Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Online published: 2025-08-16
Supported by
National Natural Science Foundation of China (81900710); Shanghai Medical Key Specialist Department Project (ZK2019C09); Health Scientific Research Progress of Pudong New Distinct Health Commission (PW2019D-12); Youth Fund of Pudong New Area Zhoupu Hospital(ZPXM-2019A-02)
免疫疗法是一种快速发展的治疗自身免疫病和癌症的方法。细胞毒性T淋巴细胞抗原4（cytotoxic T lymphocyte antigen 4，CTLA-4）是适应性免疫应答的主要抑制分子，也是该领域最著名和研究最广泛的分子。CTLA-4能够通过多种机制来调节和控制免疫细胞的功能。随着对CTLA-4研究的深入，科学家已经研发出CTLA-4类似物阿巴西普和针对CTLA-4的抗体伊匹木单抗。这两种针对CTLA-4的生物制剂，在自身免疫病和肿瘤疾病的治疗中具有广阔的应用前景。
房玉蝶 祝洁 张进安 . 基于细胞毒性T淋巴细胞抗原4研发的生物制剂的临床应用进展[J]. 国际生物制品学杂志, 2021 , 44(5) : 276 -281 . DOI: 10.3760/cma.j.cn311962-20210324-00013
Immunotherapy is a rapidly developing treatment for autoimmune diseases and cancer. Cytotoxic T lymphocyte antigen 4 (CTLA-4) is the primary attenuator of adaptive immune responses and the most prominent and extensively investigated molecule in this field. CTLA-4 can regulate and control the function of immune cells through a variety of mechanisms. With further research on CTLA-4, CTLA-4-Ig Abatacept and antibody against CTLA-4 ipilimumab have been developed. These two biological agents have broad application prospects in the treatment of autoimmune diseases and tumor diseases.
/
| 〈 |
|
〉 |
沪公网安备 31010502000696号 沪ICP备05031153号-3